Aquestive Therapeutics Inc (NASDAQ:AQST) has a beta value of 2.82 and has seen 1.09 million shares traded in the recent trading session. The company, currently valued at $248.08M, closed the recent trade at $2.72 per share which meant it lost -$0.03 on the day or -0.91% during that session. The AQST stock price is -129.04% off its 52-week high price of $6.23 and 54.04% above the 52-week low of $1.25. The 3-month trading volume is 2.37 million shares.
Aquestive Therapeutics Inc (NASDAQ:AQST) trade information
Sporting -0.91% in the red today, the stock has traded in the red over the last five days, when the AQST stock price touched $2.72 or saw a rise of 11.11%. Year-to-date, Aquestive Therapeutics Inc shares have moved 34.90%, while the 5-day performance has seen it change -7.31%. Over the past 30 days, the shares of Aquestive Therapeutics Inc (NASDAQ:AQST) have changed -17.17%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Aquestive Therapeutics Inc (AQST) estimates and forecasts
Figures show that Aquestive Therapeutics Inc shares have underperformed across the wider relevant industry. The company’s shares have gained 26.74% over the past 6 months, with this year growth rate of -246.15%, compared to 14.30% for the industry. Revenue growth from the last financial year stood is estimated to be 13.70%.
8 analysts offering their estimates for the company have set an average revenue estimate of 12.38M for the current quarter. 8 have an estimated revenue figure of 12.55M for the next ending quarter. Year-ago sales stood 13.24M and 11.41M respectively for this quarter and the next, and analysts expect sales will shrink by -6.50% for the current quarter and 13.70% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 46.61% over the past 5 years.
AQST Dividends
Aquestive Therapeutics Inc is expected to release its next earnings report in July this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
